|
|
There
is a need for a simpler and potent anti-HIV regimen
that enhances adherence by reducing pill burden, while
ensuring longterm efficacy, safety and tolerability.
|
|
Objective
|
Efavirenz
(Sustiva) is an non-nucleoside reverse transcriptase
inhibitor (NNRTI) displaying high potency, safety,
tolerability and reduced pill burden. The primary
efficacy measure will be the proportion of study volunteers
who maintain low viral loads after switching to this
regimen.
|
|
|
Group
1 will receive efavirenz (Sustiva)
in combination with lamivudine (3TC) and didanosine
(DDI).
Group
2 will receive efavirenz (Sustiva)
in combination with their current NRTIs.
No
volunteer will receive placebo.
|
Inclusion
Criteria
(partial
list)
|
•
HIV+ Adult male or female 18 years or older
•
Viral
load (PCR) <50 copies (must bring in most recent
result to screening visit)
•
Must
be currently taking 2 NRTIs and a PI
•
If
female, not pregnant and willing to use a barrier
method of contraception during the study
|
|
Status
__
|
Enrolling
--
|
For
more information about participating in this study
in the Los Angeles area, please call 310.358.2429
or e-mail Corie Castro at
ccastro@aidsresearch.org
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS ReSearch Alliance
Institutional Review Board in May, 2003.
|
